• Criptovalute
  • Mercati Predittivi
  • Notizie
  • Trading Agentico
  • Articoli
  • Leghe

Cerca Criptovalute

Criptovalute di tendenza

CoinRithm

Azienda

Entità legale
Bees-x Limited
Numero società
13308136
Costituita in
England and Wales
Sede legale
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm è un servizio di informazione e ricerca gestito da Bees-x Limited. Non è autorizzato dalla Financial Conduct Authority (FCA) a svolgere attività regolamentate e nulla su questo sito costituisce consulenza finanziaria.

Esplora

CriptovaluteMercati PredittiviNotizieArticoliAgent ArenaLeghe

Funzionalità

CruscottoScambio DimostrativoTrading AgenticoPortafoglioLista di ControlloImpostazioni

Azienda

Chi SiamoMetodologiaTermini di UsoPolitica sulla RiservatezzaPolitica sui CookieDisconoscimento

Assistenza

Supporto ClientiDomande FrequentiKit per sviluppatoriDocumentazione MCP

Social

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Tutti i diritti riservati.
Disponibile su Google PlayScarica su App Store
  • Home
  • MercatiMercati Predittivi
  • Notizie
  • Cruscotto
  1. Mercati Predittivi
  2. Health & Medicine
  3. Will the FDA approve any psychedelic substance for medical use this year?
Will the FDA approve any psychedelic substance for medical use this year?

Will the FDA approve any psychedelic substance for medical use this year?

5.0% (24h)Health & MedicineOne-Off6m
KalshiKalshiVerifica disponibilitàKYC richiesto2% di commissione
Probabilità implicita attuale
Sì
Sì 32%-5.0%
Qualita del mercato

28 / 100

Bassa qualità
Volume 24h

12 €

Liquidità

712,5 €

Bassa liquidità
Bid / Ask

30.0% / 33.0%

Spread

10.0%

Spread ampio
Dati di mercato

Aggiornato 3 minuti fa

17 lug 25, 14:001 gen 27, 4:59

Trend

Esito24hProbabilità

Esito scelto

Yes32%

Regole

If the FDA approves any psychedelic substance for medical use for marketing before Jan 1, 2027, then the market resolves to Yes.

Kalshi
  • Psychedelic drugs include: LSD, Psilocybin, DMT, Mescaline, MDMA, MDA, PCP, DXM, Ibogaine, Salvia divinorum, 2C family, and Ayahuasca.
  • Important information: For purposes of this Contract:
  • The listed substances are illustrative, not exhaustive.
  • Approval of any other substance commonly recognized in scientific or FDA documentation as a psychedelic, hallucinogen, or entactogen (for example, psilocin, 5-MeO-DMT, methylone, or 2C-, DOx-, or NBOMe-family compounds) may also satisfy the Payout Criterion.
  • "Approval for medical use" means an FDA approval letter for an NDA or BLA authorizing marketing of a drug or biologic for human medical use in the United States, where a listed (or otherwise qualifying) psychedelic substance is an active pharmaceutical ingredient of the approved product.

Mercati Correlati

Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

145,3K €
Sì: 5%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

16,6K €
Sì: 10%PolymarketPOLYMARKET
Ebola pandemic in 2026?

Ebola pandemic in 2026?

8,7K €
Sì: 8%PolymarketPOLYMARKET
Manifold Markets

How many movies will gross >$1 billion in 2026?

1,3K €
0-3: 5.7%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Which disease will be eradicated next in humans?

462,5 €
Polio: 26.7%Manifold MarketsMANIFOLD MARKETS
When, where or how will Trump die?

When, where or how will Trump die?

137,8 €
2025: 0%Manifold MarketsMANIFOLD MARKETS

Attivi in questi argomenti

BitcoinBTC$62,867.10+2.52%EthereumETH$1,658.07+1.88%SolanaSOL$65.28+1.86%DogecoinDOGE$0.085+1.73%XRPXRP$1.12+0.74%BNBBNB$596.82+1.84%

Notizie Correlate

Chainalysis reveals $100 million peptide market built on cryptoCrypto NewsGray peptide vendors embrace stablecoins as safety fears deepenCrypto NewsOpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.NewsBrian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto News

Regole

If the FDA approves any psychedelic substance for medical use for marketing before Jan 1, 2027, then the market resolves to Yes.

Kalshi
  • Psychedelic drugs include: LSD, Psilocybin, DMT, Mescaline, MDMA, MDA, PCP, DXM, Ibogaine, Salvia divinorum, 2C family, and Ayahuasca.
  • Important information: For purposes of this Contract:
  • The listed substances are illustrative, not exhaustive.
  • Approval of any other substance commonly recognized in scientific or FDA documentation as a psychedelic, hallucinogen, or entactogen (for example, psilocin, 5-MeO-DMT, methylone, or 2C-, DOx-, or NBOMe-family compounds) may also satisfy the Payout Criterion.
  • "Approval for medical use" means an FDA approval letter for an NDA or BLA authorizing marketing of a drug or biologic for human medical use in the United States, where a listed (or otherwise qualifying) psychedelic substance is an active pharmaceutical ingredient of the approved product.